CANADA - 2025/04/03: In this photo illustration, the Intuitive Surgical logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesIntuitive Surgical stock (NASDAQ: ISRG) experienced an impressive 17% increase in extended trading on Tuesday, October 21, 2025, after significantly exceeding investor expectations with its Q3 results across all key metrics. The pioneer in medical robotics not only posted st ...

截至2025年第三季度末，公司现金、现金等价物及投资总额为84.3亿美元，较季度初减少11亿美元， 2024年 12 月 31 日约为88亿美元。减少主因是用于普通股回购及资本支出的现金，部分被经营活动现金 抵消。此外，该公司以19.2亿美元回购了400万股股票。 截至发稿，直觉外科在盘后交易中上涨超17%，报543.00美元。 据了解，营收增长主要源于手术量增加、达芬奇手术系统部署量提升及设备装机量扩大。本季度，公司 投放427台达芬奇系统，较上年同期的379台增长明显;Ion系统投放50台，去年同期为58台。手术量同比 增长约20%，其中达芬奇系统手术量增长约19%，Ion系统手术量增长约52%。 智通财经APP获悉，美东时间10月21日(周二)盘后，微创护理领域全球技术领导者与机器人辅助手术先 驱直觉外科公司(ISRG.US)发布了截至2025年9月30日的季度财务业绩。财报显示，该公司第三季度营收 达25.1亿美元，较2024年第三季度的20.4亿美元增长23%;按GAAP计算，净利润为7.04亿美元，每股摊 薄收益1.95美元，上年同期分别为5.65亿美元和1.56美元;非GAAP净利润则为8.67 ...

Investment Rating - The report assigns a "Hold" rating for the company with a target price of $526.85, indicating a potential upside of 7.1% from the current price of $492.06 [3][4]. Core Insights - The company experienced a strong revenue growth of 25.2% year-over-year in Q4, contributing to an annual revenue of $8.35 billion, which is a 17.2% increase compared to the previous year [1]. - The growth was driven by an increase in surgical procedures, particularly in the U.S. and several international markets, with a 17% increase in da Vinci surgeries, totaling 2.68 million procedures [1]. - The company is in the process of expanding its product offerings, particularly with the upcoming full launch of the DV5 surgical robot system, which is expected to be widely available by mid-2025 [2]. Financial Performance - For the fiscal year 2024, the company reported a net profit of $2.34 billion, reflecting a 28.6% increase, with a net profit margin of 28.0% [1]. - The non-GAAP gross margin improved by 1.0 percentage points to 69.1% due to increased production capacity and sales volume [1]. - The company anticipates a surgical growth rate of 13%-16% for 2025, with gross margins expected to remain between 67%-68% [3]. Future Outlook - The company plans to open new manufacturing facilities for the DV5 and Ion systems in California, as well as endoscope manufacturing plants in Germany and Bulgaria [2]. - The anticipated acquisition of businesses in Italy, Spain, and Portugal is expected to positively impact profits once completed in the first half of 2026 [2]. - Capital expenditures are projected to be between $650 million and $800 million, with other income expected to rise to $370 million to $400 million [3].